Goldman Sachs Views Lab Stocks as Attractive, Neutral on Diagnostics; LabCorp (LH) Top Pick, Myriad (MYGN) the Bottom
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Qiagen (QGEN) Agrees to Acquire STAT-Dx
January 31, 2018 4:35 PM ESTQIAGEN N.V. (NYSE: QGEN) announced today it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.
The... More
Qiagen (QGEN) Tops Q4 EPS by 2c, Beats on Revenues; 'Sets FY18 Outlook for Further Growth in Adj. Net Sales & Adj. EPS'
January 31, 2018 4:15 PM ESTQiagen (NASDAQ: QGEN) reported Q4 EPS of $0.43, $0.02 better than the analyst estimate of $0.41. Revenue for the quarter came in at $396.6 million versus the consensus estimate of $393.33 million.
Solid Q4 results as QIAGEN achieves full-year 2017 targets: Q4 2017: Net sales $396.9 million (+8% actual, +5% CER);... More